Melanoma follow-up - Which examinations are useful?;Diagnostische anstrengungen in der Melanomnachsorge welche werden belohnt?

H+G Zeitschrift fur Hautkrankheiten

Volumn 74, Issue 7-8, 1999, Pages 392-398

  Hofmann, U ^a   Schoffel A ^b   Stein, A ^a   Schadendorf, D ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Diagnostic yield; Efficacy; Follow up; Melanoma

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOGRAPHY; FOLLOW UP; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; REVIEW; THORAX RADIOGRAPHY;

EID: 0032880576     PISSN: 03010481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Balch, C. M., S. J. Soong, T. M. Murad, J. W. Smith, W. A. Maddox & J. R. Durant (1983): A multifactorial analysis of melanoma: IV. prognostic factors in 200 melanoma patients with distant metastases. J Clin Oncol 1,126-134.
2. Barth, A., L A. Wanek & D. L Morton (1995): Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181, 193-201.
3. Basler, G. C., D. J. Fader, A. Yahanda, V. K. Sondak & T. M. Johnson (1997): The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol 36,403-408.
4. Bassères, N., J. J. Grob, M. A. Richard, X. Thirion, H. Zarour, C. Noe, A. M. CoIIet-Vilette, I. Lota & J. J. Bonerandi (1995): Cost-effectiveness surveillance of stage I melanoma. Dermatology 191,199-203.
5. Bastien, M., M. H. Tessier, B. Legoux, P. Litoux, B. Bureau & B. Dréno (1997): Usefulness of paraclinical follow-up in stage I melanoma. Arch Dermatol 133,1462-1463.
6. Baughan, C. A., V. L Hall, B. J. Leppard & P. J. Perkins (1993): Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 5,174-180.
7. Berwick, M. (1998): Epidemiology: current trends, risk factors, and environmental concerns. In: Cutaneous Melanoma. Eds.: C. M. Balch et al., pp. 551-571, Quality Medical Publishing, St. Louis.
8. Binder, M., H. Kittter, A. Steiner, R. Dorfner, K. Wolff & H. Pehamberger (1997): Lymph node sonography versus palpation for detecting recurrent disease in patient with malignant melanoma. Eur J Cancer 33,1805-1808.
9. Blum, A., W. Stroebel, B. Schiagenhauff, G. Rassner & C. Garbe (1998): Lymphknotensonographie führt zur Erstentdeckung von regionären Metastasen bei einem Drittel der Patienten mit Melanom. In: Dermatologie-Leitlinien und Qualitätssicherung für Diagnostik und Therapie. Eds.:C. Garbe et al., pp. 262-264, Springer, Berlin.
10. Bosserhoff, A. K., M. Kaufmann, B. Kaluza, l. Bartke, H. Zirngibl, R. Hein, W. Stolz & R. Buettner(1997): Melanoma-inhibiting activity, a novel serum marker for progression of malig-, nant melanoma. Cancer Res 57,3149-3153.
11. Buzaid, A. C., M. I. Ross, C. M. Balch, S. J. Soong, W. H. McCarthy, L. Tinoco, P. Mansfield, J. E. Lee, A. Bedikian, 0. Eton, C. Plager, N. Papadopolous, S. S. Legha & R. S. Benjamin (1997): Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15,1039-1051.
12. Buzaid, A. C., L. Tinoco, M. I. Ross, S. S. Legha & R. S. Benjamin (1995): Role of computed tomography in the staging of patients with localregional metastases of melanoma. J Clin Oncol 13, 2104-2103.
13. Buzzell, R. A. & J. A. Zitelli (1996): Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34, 798-803. -
14. Calabro, A., S. E. Singletary & C. M. Balch (1989): Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124,1051-1055.
15. Cascinelli, N., M. Vaglini, M. Nava, M. Santinami, R. Marolda, D. Rovini, C. Clemente, R. Bufalino & A. Morabito (1984): Prognosis of skin melanoma with regional nodal disease (stage II). J Surg Oncol 25,240-247.
16. Coit, D. G., A. Rogatko & M. F. Brennan (1991): Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 214,627-636.
17. Eggermont, A. M. (1996): 'Nachbeobachtung von Patienten mit einem Melanom im Stadium l nach Exzision des Primärtumors: einfach und kosteneffizient. Onkologe 2,476-480.
18. Eton, O., S. S. Legha, T. E. Moon, A. C. Buzaid, N. E. Papadopoulos, C. Plager, A. M. Burgess, A. Y. Bedikian, S. Ring, Q. Dong, A. B. Glassman, C. M. Baten & R. S. Benjamin (1998): Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16,1103-1111.
19. Fraker, D. L (1997): Surgical issues in the management of melanoma. Curr Opin Oncol 9, 183-188.
20. Garbe, C. (1997): Epidemiologie des Hautkrebses. In: Dermatologische Onkologie. Eds.: C. Garbe et al., pp. 683-692, Springer, Berlin
21. GlVIO-Investigators (1994): Impact of foliow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 271, 15871592.
22. Gläser, R. (1997): Tumormarker des malignen Melanoms. In: Dermatologische Onkologie. Eds.: C. Garbe et al., pp. 324-329, Springer, Berlin.
23. Goerz, G., R. Schulte-Beerbuhl, K. Roder, W. D. Schoppe, C. Munchhoff & R. M. Jungblut (1986): Malignant melanoma: which examinations are useful in staging and follow up? Dtsch Med Wochenschr 111,1230-1233.
24. Harpole, J., D. H. (1992): Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 103, 743-750.
25. Huang, C. L, N. Provost, A. A. Marghoob, A. W. Kopf, L Levin & R. S. Bart (1998): Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39, 451-463.
26. Hustinx, R., P. Paulus, N. Jacquet, G. Jerusalem, T. Bury & P. Rigo (1998): Clinical evaluation of whole-body 18F-fIuorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 9, 397-401.
27. Johnson, T. M., D. J. Fader, A. E. Chang, A. Yahanda, J. W. Smith, K. R. Hamlet & V. K. Sondak (1997): Computed tomography in staging patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 4, 396402.
28. Karakousis, C. P., A. Velez, D. L Driscoll & H. Takita (1994): Metastasectomy in malignant melanoma. Surgery 115,295-302.
29. Kaufmann, R., W. Tilgen & C. Garbe (1998): Standards Dermatologische Onkologie-Malignes Melanom. Hautarzt 48, S30-S38.
30. Kersey, P. A., N. A. Iscoe, J. A. P. Gapski, D. Osoba, L. From, G. DeBoer & l. C. Quirt (1985): The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 72, 614-617.
31. Khansur, T., J. Sanders & S. K. Das (1989): ' Evaluation of staging workup in malignant melanoma. Arch Surg 124,847-849.
32. Kuvshinoff, B. W., C. K. Kurtz & D. G. Coit (1997): Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 4, 252-258.
33. Lee, Y. T. (1983): Noninvasive screening tests for metastatic melanoma: rationale and results. Am J Clin Oncol 6,225-233.
34. Mooney, M. M., M. Kulas, B. McKinley, A. M. Michalek & W. G. Kraybill (1998): Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol 5,54-63.
35. Mooney, M. M., C. Mettlin, A. M. Michalek, N. J. Petrelli & W. G. Kraybill (1997): Ufe-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences. Cancer 80,1052-1064.
36. Moser, E. &T. Krause (1997): Deutsche Gesellschaft für Nuklearmedizin e.V. Nachrichten: Konsensus-Onko-PET. Nuklearmedizin 36, 4546.
37. Nambisan, R. N., G. Alexiou, P. A. Reese & C. P. Karakousis (1987): Early metastatic patterns and survival in malignant melanoma. J Surg Oncol 34,248-252.
38. Orfanos, C. E., E. G. Jung, G. Rassner, H. H. Wolff & C. Garbe (1994): Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Hautarzt 45,285-291.
39. Rinne, D., R. P. Baum, G. Hor & R. Kaufmann (1998): Primary staging and follow-up of high risk melanoma patients with whole-body 18Ffluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82,1664-1671.
40. Ross, M. I. (1996): Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. Surg Clin North Am 76,1423-1432.
41. Rosselli Del Turco, M., D. Palli, A. Cariddi, S. Ciatto, P. Oacini & V. Distante (1994): Intensive diagnostic follow-up after treatment for primary breast cancer: a randomized trail. JAMA 271, 1593-1597.
42. Shumate, C. R., M. M. Urist & W. A. Maddox (1995): Melanoma recurrance surveillance. Patient or physician based? Ann Surg 221, 566571.
43. Soong, S. J., R. A. Harrison, W. H. McCarthy, M. M. Urist & C. M. Balch (1998): Factors affecting survival following local, regional or distant recurrence from localized melanoma. J Surg Oncol 67,228-233.
44. Steinert, H. C., R. Boni, S. P. Ullrich, G. K. von Schulthess, G. Burg & R. Dummer (1998): Cost effectiveness of whole-body positron emission tomography (PET) in staging of malignant melanoma. J Invest Dermatol 110,721.
45. Steinert, H. C., R. A. Much Boni, A. Buck, R. Boni, T. Berthold, B. Marincek, G. Burg & G. K. von Schulthess (1995): Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 195,705-709.
46. Tafra, L, P. S. Dale, L A. Wanek, K. P. Ramming & D. L. Morion (1995): Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110,1)9-129.
47. Troell, R. J. & D. J. Terris (1995): Detection of métastases from head and neck cancers. Laryngoscope 105,247-250.
48. Wagner, J. D., D. Schauwecker, G. Hutchins & J. J. R. Coleman (1997): Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic métastases in melanoma. J Surg Oncol 64,181-189.
49. Weiss, M., C. L. Loprinzi, E. T. Creagan, R. J. Dalton, P. Novotny & J. R. O'Fallon (1995)'. Utility of follow-up tests for detecting recurrent di-sease in patients with malignant melanomas. JAMA 274,1703-1705.